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A bstract
In  the present study, w e show  that the expres-
sion of type 2 glucose transporter isoform (GLUT2) 
could  be regu lated by PPA R -γ  in  the liver. R osi-
g litazone, PPA R -γ  agonist, activated the G LU T2 
m R N A  level in  the prim ary cultured  hepatocytes  
and Alexander cells, when these cells w ere trans-
fected w ith PPA R -γ/R XR -α. W e have localized the  
peroxisom e pro liferator response elem ent in  the  
m ouse G LUT2 prom oter by serial deletion studies  
and site-d irected  m utagenesis. C hrom atin  im m u -
noprecip itation assay using  ob/ob  m ice a lso  
show ed that PPAR-γ rather than PPAR-α binds to  
the -197/-184 region of G LU T2 prom oter. Taken  
together, liver G LU T2 m ay be a  d irect target of 
PPA R -γ lig an d  con tribu tin g  to  g lu co se  tran sport 
into liver in  a condition w hen PA PR -γ  expression  
is  increased  as in  type 2  d iabetes or in  severe  
obesity.
K eyw ords: GLUT2; liver; promoter; PPAR-γ; rosiglita-
zone; type 2 diabetes
In troduction
Recently, peroxisome proliferator-activated receptor 
(PPAR) family draws much attention in the treatment 
of type 2 diabetes. Three isoforms, encoded by sepa-
rate genes, have been identified so far: PPAR-α, 
PPAR-β(δ), and PPAR-γ (Sher et al., 1993). PPAR-α 
is highly expressed in hepatocytes, enterocytes, pro-
ximal tubular epithelium of kidney, and cardiac mus-
cle, and the expression pattern parallels, to a certain 
extent, the sensitivity of various tissues to the β-oxi-
dation induction by synthetic peroxisome proliferators 
(Spiegelman, 1998; Guillemain et al., 2000). PPAR-γ 
is known to be involved in adipogenesis, and main-
tenance of differentiation is important in breast, colon, 
and urinary bladder function. PPAR-γ is a member of 
the nuclear hormone receptors that contains the li-
gand-dependent activation domain (AF-2) (Picard et 
al., 2002). Upon ligand binding, PPAR-γ heterodimeri-
zed with retinoid X receptor (RXR)-α binds to the 
PPAR response element (PPRE) and activates target 
gene transcription. Thiazolidinediones (TZDs) are a 
class of antidiabetic agents that improve insulin sensi-
tivity in various animal models of diabetes (Cavaghan 
et al., 1997; Rahimian et al., 2001). Patients with a 
dominant-negative mutation in the PPAR-γ gene show 
severe hyperglycemia, which provides a genetic link 
between PPAR-γ and type 2 diabetes (Barroso et al., 
1999). So far, a mechanism of antihyperglycemic ef-
fect of TZDs on the liver is considered to be rather 
indirect (Jiang et al., 2002), partly because hepatic 
expression of PPAR-γ is rather low, and adipocytes 
specific deletion of the PPAR-γ gene affects the blood 
glucose level (He et al., 2003). However, in the patho-
logical state, as in obesity and type 2 diabetes pa-
tients, the expression of PPAR-γ is known to be in-
creased (Rahimian et al., 2001). Thus, the direct role 
of PPAR-γ  ligand on the genes involved in hepatic 
glucose metabolism cannot be ruled out. Previously, 
we have characterized the peroxisom proliferator-ac-
tivator response element (PPRE) in the promoter 
regions of rat GLUT2 (Kim et al., 2000) and gluco-
kinase (Kim et al., 2002) gene and reported their phy-
siological implications in the insulin secretion in re-
sponse to changing blood glucose level in the pan-
creas of type 2 diabetic Zucker diabetic fatty (ZDF) 
rats. We also showed that liver type glucokinase (L- 
GK) was directly upregulated by TZDs in its promoter 
(Kim et al., 2004). Because L-GK functions very 
closely with GLUT2 in transporting glucose into liver, 
it is possible that TZDs can activate both GLUT2 and 
L-GK gene in a coordinate manner. 
  To explore this possibility, we have dissected 
mouse GLUT2 promoter and identified a PPRE in the 
-197/-184 region. We also demonstrated that PPAR-α 
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is not a good inducer of GLUT2 expression whereas 
PPAR-γ stimulated the endogenous GLUT2 mRNA 
expression in primary mouse hepatocytes when PPAR- 
γ was ectopically expressed. Also, in the liver of ob/ 
ob mice, where PPAR-γ expression is increased (Ed-
vardsson et al., 1999), the PPAR-γ ligand upre-
gulated the GLUT2 expression whereas PPAR-α li-
gand did not affect its expression, indicating that 
PPAR-γ may contribute to lowering blood glucose le-
vel by activating GLUT2 gene expression in the dia-
betic liver.
M ateria ls and M ethods
M aterials
Wy14,643 (20 mM in 19% BSA and 5% dimethyl sul-
foxide), 9-cis retinoic acid (2 mM in 50% ethanol and 
50% dimethyl sulfoxide), and rosiglitazone (2 mM in 
5% BSA and 5% dimethly sulfoxide) were diluted to 
the final concentration of 20 µM, 1 µM, and 2 µM 
respectively. Wy14,643 and 9-cis retinoic acid were 
purchased from Sigma-Aldrich (St. Louis, MO). Rosi-
glitazone was kindly donated by GlaxoSmithKline, UK. 
PPAR-α and PPAR-γ antibodies were purchased from 
PPMX Perseus Proteomics Inc, Japan.
C onstruction of p lasm ids
The promoter region (-1112/+1) of the mouse GLUT2 
gene was cloned into the KpnI/XhoI site of the pGL3- 
basic vector (Promega, Madison, WI) to generate 
pMGT2-1112. Deletion constructs of mouse GLUT2 pro-
moter were prepared from pMGLUT2 (pMGT2-1112/ 
+1). pMGT2d-890 was prepared by excising out 222 
bp fragment of SalI and EcoR I digestion. pMGT2d- 
389 was constructed by digesting with SalI and PstI 
from the pMGT2-1112/+1. Other deletion constructs of 
mouse GLUT2 promoter were prepared by digesting 
pMGT2-1112/+1 after EcoR I sites was generated by 
PCR-based site-directed mutagenesis kit (Stratagene, 
La Jolla, CA), and named pMGT2d-283, pMGT2d-166, 
and pMGT2d-57, respectively. The PPRE truncated 
construct, pMGT2d-283/-166, was also prepared from 
pMGT2d-389 with the same method described above. 
Mutant constructs pMGT2m-389mut1 (mut1), pMGT2m- 
389mut2 (mut 2), and pMGT2m-389mut1+2 (mut1+2) 
were produced by introducing substitution mutations 
into pMGT2d-389 using site-directed mutagenesis. The 
sequences of constructs were confirmed by dideoxy- 
DNA sequencing method. Expression plasmids, pCMX- 
mPPAR-α, pCMX-mPPAR-γ and pCMX-mRXR-α were 
kind gifts from Drs. R. M. Evans and D. J. Mangel-
sdorf (Mangelsdorf et al., 1992; Kliewer et al., 1994). 
Control vector, pCMX was prepared from  pCMX- 
mRXR-α by excising out the 1.5 kb fragment of 
mRXR-α cDNA. The dominant negative plasmid of 
NF-Y (△4NF-YA13m29; NF-Ym) was provided by Dr. 
R. Mantovani (Gurtner et al., 2003).
Prim ary hepatocytes preparation from  m ouse liver
Hepatocytes were isolated from male ICR mouse (ap-
proximately 30 g) by the collagenase perfusion meth-
od (Seglen, 1972). Dissociation into individual hepato-
cytes was performed in Dulbecco's modified Eagles' 
medium (DMEM) containing 10% (v/v) heat inactiva-
ted fetal calf serum (FCS), 0.1 IU/ml insulin, 10 nM 
dexamethasone, 25 mM glucose, 100 U/ml penicillin 
G, 100 µg/ml streptomycin and 0.25 µg/ml amphoteri-
cin B. For each hepatocyte preparation, cell viability 
was checked by the exclusion of trypan blue. 
C ell culture and transient transfection
Alexander cells (Human epithelial hepatoma cell lines; 
American Type Culture Collection number CRL-8024) 
were maintained as monolayer cultures and grown in 
Dulbecco's modified Eagle's medium (DMEM) (Invitro-
gen) supplemented with 10% (v/v) fetal bovine serum, 
100 U/ml penicillin, and 100 µg/ml streptomycin. Plas-
mid DNAs were purified using Qiagen Midiprep kit 
columns (Qiagen, Valencia, CA). Transient transfec-
tion and luciferase assays were performed as descri-
bed previously (Cha et al., 2001). Briefly, cells were 
plated in six-well tissue culture plates at a density of 
1×106 cells/well in 2 ml of medium. After a 20 h 
attachment period, transfections with 0.5 µg of each 
construct of GLUT2 promoter and control vector were 
performed with LipofectAMINE PLUS reagent (Life 
Technologies, Carlsbad, CA), according to the ma-
nufacturer's protocol. After 24 h transfection, the me-
dium was replaced by a medium containing Wy 
14,643 (20 µM, final concentration), rosiglitazone (2 
µM, final concentration) and 9-cis retinoic acid (1 µM, 
final concentration) respectively. Cells were cultured 
further for 24 h and harvested in reporter lysis buffer 
(Promega). Luciferase data were expressed as luci-
ferase activity corrected by β-galactosidase activity in 
the cell lysate. Each transfection was performed in tri-
plicate and repeated three to five times. 
N uclear extracts preparation
Nuclear extract from liver of male Sprague-Dawley 
rats was prepared as described by Gorski et al. (Gor-
ski et al., 1986). Protein concentration was deter-
mined by the method of Bradford (Bradford, 1976). 
Electrophoretic m obility  shift assay (EM SA )
The oligonucleotide probe GLUT2-PPRE was labeled 
as described previously (Kim et al., 2002b). Ten pmo-
les of single stranded sense oligonucleotide were la-
beled with [γ-32P] ATP using T4 polynucleotide kinase 
and annealed with 50 pmoles of unlabeled antisense 
oligonucleotides. The resulting double stranded oli-
gonucleotides were purified by Sephadex G50 spin 
column. The labeled probe (10,000 cpm) was in-
cubated with 5 µg of nuclear extract from rat liver for 
30 min on ice. The binding reactions were same as 
described (Kim et al., 2000). To perform supershift 
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assay, the binding mixtures were incubated for 10 min 
at room temperature in the presence of 1 µ l of anti- 
PPARγ  (Kim et al., 2002a). Protein-DNA complexes 
were resolved from the free probe by electrophoresis 
at 4oC on a 4% polyacrylamide gel in 0.25 × TBE 
buffer (1 × TBE contained 9 mM Tris, 90 mM boric 
acid, 20 mM EDTA, pH 8.0). The dried gels were ex-
posed to X-ray film at -70oC with an intensifying 
screen. The oligonucleotide sequences used in EMSA 
were as follows: GLUT2-PPRE, 5'-CTGTGCTCAAGC 
CACAAGTCATTGGGGTAAAGGGT-3'; mut1, 5'-CTG 
T G C T C A A G C C A C ta c c g tT T G G G G T A A A G G G T -3 ' ; 
mut2, 5'-CTGTGCTCAAGCCACAAGTCATtcagtgAAA-
GGGT-3'; mut1+2, 5'-CTGTGCTCAAGCCACtaccgtT-
tcagtgAAAGGGT-3'. Mutated bases are shown in lower-
case letters. The oligonucleotide for CYP4A6-PPRE 
(PPRE of cytochrome p450 gene) (Muerhoff et al., 
1992) was synthesized. 
A nim als and drug adm in istration
5-week-old male ob/ob mice and lean littermates 
(Jackson Laboratories, Bar Harbor, ME) were housed 
in plastic cages on a 12:12 light/dark cycle with free 
access to water and food (Purina 5008). After 2 
weeks of acclimation, animals were weighed, bled via 
the tail vein, and assigned to treatment groups based 
on starting glucose values (first criterion) and initial 
body weights (second criterion). Diabetes were con-
firmed (glucose level; 296 mg/dl) by checking the 
plasma glucose levels. Before treatment of drug, oral 
glucose tolerance test (OGTT) was performed (0-day), 
and mice were gavaged once daily with vehicle, ro-
siglitazone (30 mg/kg) for 7 days (7-day). Animals 
were weighed and performed oral glucose tolerance 
test again. At the end of the experiments, animals 
were sacrificed by cervical dislocation under isoflurane 
anesthesia, and livers were rapidly excised, flash fro-
zen in liquid nitrogen, and stored at -70oC for RNA 
analysis. 
R N A  preparation and reverse transcrip tion-
polym erase chain  reaction (R T-PC R )
Total RNA was isolated from primary hepatocytes us-
ing TRIzol reagent by manufacturer's protocol (Life 
Technologies). For RT-PCR, first strand cDNA was 
synthesized from 3 µg of total RNA using random 
hexamer and Superscript II reverse transcriptase (Life 
Technologies). One µl of the reverse transcription re-
action mixture was amplified with primers specific for 
GLUT2 and glyceraldehyde 3-phosphate dehydroge-
nase (G3PDH) in the total volume of 50 µl. Linearity 
of the PCR was tested by amplification cycles be-
tween 20-30. According to test amplification profile, 
samples were amplified using the following parame-
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F ig u re  1 . Effect of PPAR-γ  and PPAR-γ  ligands on the 
GLUT2 mRNA content. pGLM and pMGT2-1112 were 
cotransfected with 100 ng of the indicated PPAR-γ  and 100
ng of RXR-α  expression vectors into Alexander cell (A) and
mouse primary hepatocytes (B). After trasfection, 2 µ M 
rosiglitazone and 1 µ M 9-CR  for receptors were treated to 
Alexander cell and mouse primary hepatocytes maintained at
25 mM glucose concentration for 24 h. Total RNA was 
extracted for each group and subjected to RT-PCR (A) and 
Northern blot analysis (B). (C) Dose response activation of 
GLUT2 promoter construct by PPAR-γ  in Alexander cell. Ten
to 200 ng of PPAR-γ  and 100 ng of RXR-α  were used for
transfection. The luciferase activities were normalized with 
respect to β -galactosidase activities. Results are the mean±
S.D. of three independent experiments in triplicate.
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ters: 94oC for 30 s, 58oC for 30 s, 72oC for 30 s. 
G3PDH was used as an internal control for quality 
and quantity of RNA. Primers used in PCR were fol-
lows: GLUT2-Ex2-sense, 5'-ATCACCGGAACCTTGG-
CTTTCACT-3', GLUT2-Ex5-sense, 5'-GGCTAATTTC-
AGGACTGGTT-3'; GLUT2-Ex6R-antisense, 5'-TTTC 
TTTGCCCTGACTTCCT-3'; G3PDH-sense, 5'-ACCAC 
AGTCCATGCCATCAC-3'; G3PDH-antisense, 5'-TCC 
ACCACCCTGTTGCTGTA-3'.
N orthern  blo t hybrid ization of m R N A
Aliquots of total RNA (20 µg) from each sample were 
denatured with RNA sample loading buffer (20 mM 
MOPS, pH 7.0, 2 mM sodium acetate, 1 mM EDTA, 
8% formaldehyde, 50% formamide), and subjected to 
electrophoresis in a 0.9% denaturing formaldehyde a-
garose gel, and transferred to Nylon membrane. The 
cDNA of mouse GLUT2 was labeled with [α-32P] 
dCTP using Rediprime Labeling Kit (Amersham Bio-
sciences) and used as a probe. The membranes were 
hybridized with the probe for 2 h at 65oC with Rapid- 
Hybrid buffer (Amersham Biosciences). After hybridi-
zation, the membrane was washed twice with high 
salt washing buffer (0.1% SDS, 2 X SSC) at room 
temperature for 30 min followed by low salt washing 
buffer (0.1% SDS, 0.1 X SSC) at 65oC for 15 min. 
The membrane was exposed to X-ray film with 
intensifying screen at -70oC.
C hrom atin  im m unoprecipitation  (C hIP) assay
The ChIP assay protocol was adapted from methods 
as described by Duong et al. (Duong et al., 2002). 
Adult male lean (+/+) and diabetic (ob/ob) mice (blood 
glucose level;＞ 240 mg/dl) had free access to Pu-
rina chow. The livers were perfused with serum- free 
Dulbeco's modified Eagle's medium (DMEM) for 5 min 
and cross-linked with 5% formaldehyde in serum-free 
DMEM for 5 min. The livers were homogenized, pel-
leted by centrifugation at 2000 rpm for 4 min at 4oC, 
and resuspended in SDS lysis buffer (1% SDS, 10 
mM EDTA, 50 mM Tris-HCl, pH 8.0). The lysate was 
sonicated on ice for 3 min at a setting of cycle 0.8, 
amplitude 80 and sheared to 100-600 bps. To provide 
a positive control (input) for each condition, one un-
diluted aliquot was retained for further processing in 
parallel with all the other samples at the reversal of 
cross-linking step. To reduce nonspecific background, 
each chromatin sample (1 ml) was precleared with 60 
µ l of protein A/G-agarose (Santa Cruz Biotech, CA), 
supplemented with 200 µg/ml sonicated salmon s-
perm DNA (Stratagene), and the beads were pel-
leted. Chromatin complexes in the supernatant were 
immunoprecipitated overnight at 4oC using 30 µg of 
primary antibody, or without antibody. Immune com-
plexes were collected with 60 µl of protein A/G-aga-
rose including 200 µg/ml of salmon sperm DNA. Pro-
moter-specific PCR primers were as follows: GLUT2 
promoter (sense, 5'-TGCCTCGGCTTCCACAAAAG- 
3', antisense, 5'-GTGGATGAATAGCTGACCAG-3').
Statistics
All transfection studies were carried out in three se-
parate experiments, where triplicate dishes were trans-
fected. Data are expressed as means ± S.D. Statisti-
cal analysis was carried out using Microsoft Excel 
software (Microsoft, Redmond, WA).
R esu lts
Effect o f PPA R -γ  on the G LU T2 expression  
As shown in Figure 1A, RT-PCR of the exons of 
GLUT2 revealed that transfection of PPAR-γ/RXR-α 
with rosiglitazone induced the GLUT2 expression 
when compared to untransfected Alexander cell line 
(control), whch was maintained at the 25 mM glucose 
concentration. Northern blot analysis showed that 
GLUT2 expression was not increased by Wy14,643/ 
9-cis retinoic acid treatment at 25 mM glucose con-
centration in mouse primary hepatocytes (data not 
shown). However, Rosiglitazone/9-cis retinoic acid 
treatment induced GLUT2 mRNA level. GLUT2 mRNA 
was not increased by transfecting PPAR-γ/RXR-α 
when their ligands were not added to the culture me-
Figure  2 . GLUT2 promoters are responding to PPAR-γ . (A) Sequence
comparison of the proximal region of GLUT2 gene. (B) Schematic 
diagram of GLUT2 promoter constructs from human, mouse, and rat. 
(C) Responsiveness of GLUT2 promoter constructs to PPAR-γ . De-
tailed experimental conditions are the same as described in Figure1.
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dium (Figure 1B). To determine whether PPAR-γ re-
gulates GLUT2 promoter activity, we constructed 
mouse GLUT2 promoter construct (pmGT2-1112) and 
observed their responsiveness (Figure 1C). The GLUT2 
promoter construct was activated by transfected 
PPAR-γ expression vector from 10 ng to 80 ng) in 
a dose dependent manner, suggesting that the pro-
moter is responding to PPAR-γ specifically (Figure 
1C). 
Localization and identification of PPR E in  the  
G LU T2 prom oter 
Figure 2A shows the sequence comparison of the 
proximal regions of GLUT2 gene between species. 
Unlike human and rat GLUT2 promoter, mouse pro-
moter seems to contain NF-Y binding sites in the 
DR+1 consensus sequence (Boxed region). For the 
comparison of the GLUT2 promoter activity to 
PPAR-γ, part of the proximal regions of GLUT2 gene 
was subcloned into luciferase vector (Figure 2B) and 
named pHGT2 (human), pMGT2 (mouse), and pRGT2 
(rat), respectively. As shown in figure 2C, all the con-
structs showed good responsiveness to PPAR-γ and 
pMGT2 showed the strongest promoter activity.
To identify and characterize a functional PPRE invol-
ved in regulating the mouse GLUT2 promoter activity, 
we generated serially deleted 5' flanking regions (from 
-1112, -890, 389, -283, -166, and -57 to +1) and 
truncated PPRE (-283/-166) in pMGT2d-389 and 
examined their responsiveness to PPAR-γ  in Alex-
ander cells (Figure 3A). The promoter activity was 
well maintained down to -283 region. Further deletion 
to -166 region resulted in a dramatic drop in the lu-
ciferase activity which was assayed in Alexander cell 
line (Figure 3B) and primary hepatocytes (Figure 3C), 
suggesting that the PPRE might be present between 
-283 and -166. Internal deletion between -283 and 
-166 also diminished the promoter activity (Figure 3B). 
  Computer-based analysis of the sequence sug-
F ig u re  3 . Localization of PPRE in the mouse GLUT2 promoter. (A) Structure of serial deletion and internal deletion (d-283/-166) constructs of 
pMGT2-1112. The indicated numbers represent bases from ATG codon as +1. Cells were cotransfected with each luciferase construct with or
without PPAR-γ /RXR-α  expression plasmids into Alexander cell (B) or mouse primary hepatocytes (C). All results were normalized with respect
to β -galactosidase activities and were shown as relative fold increase in the luciferase activities compared to those of control. Normalized luciferase
activities are shown as means ± S.D. of three independent experiments in triplicate.
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gested that the region between -206 and -147 may 
contain a putative DR+1 element which is known to 
bind PPAR isoforms (Figure 2A). The binding of 
PPAR isoforms to putative GLUT2-PPRE was ana-
lyzed by EMSA using rat liver nuclear extract. Figure 
4A shows the putative DR+1 sequence as well as 
NF-Y binding sites overlapped with DR+1 in the 
GLUT2 promoter. EMSA experiment using rat liver 
nuclear extract showed that faster moving protein- 
DNA complex (lower band) could be PPAR-γ because 
unlabeled CYP4A6-PPRE (Muerhoff et al., 1992) effi-
ciently competed with PPARs/RXR-α complex forma-
tion (Figure 4B, lane 4) and the complex was su-
pershifted by PPAR-γ antibody (Figure 4B, lane 5). 
To confirm the PPAR-γ binding sequence, competition 
assay using mutant versions (mut1, mut2, and mut 
1+2, Figure 4A) of putative PPRE were performed 
(Figure 4C). Mut1+2 lost the ability to compete the 
formation of faster and slower DNA-protein complex 
(lane 6) whereas mut1 did not compete the formation 
of faster complex (lane 4) suggesting that mut1 region 
is critical for PPAR binding. Mut2 did not compete the 
formation of slower complex (lane 5) when compared 
to mut1. Instead, the slowly migrating band was com-
peted by NF-Y consensus sequence (Figure 4C, lane 
7) (Raymondjean et al., 1991) and the addition of 
mut2 to reaction mixture failed to compete the slowly 
migrating DNA complex (Figure 4C, lanes 5). These 
F ig u re  4 . Effect of mutation at the putative PPRE of GLUT2 promoter. (A) Sequences of wild type (GLUT2-PPRE) and mutated oligonucleotides
(mut1, mut2, and mut1+2) are shown. Putative GLUT2 PPRE sequence is compared with conventional DR+1. The mutated bases were represented
by bold characters. Putative NF-Y consensus sequence is indicated by gray box. (B) EMSA of GLUT2-PPRE (from -211 bp to -177 bp) using
rat nuclear extract. Thirty pmoles of [32P]-labeled double-stranded oligonucleotide were incubated with 5 µ g of rat liver nuclear extracts (RLNE)
in the presence of 100-fold molar excess of the indicated cold competitors. For the supershift assay, 1 µ g of anti-PPAR-γ  antibody was used.
Competitors are as follows: self; GLUT2-PPRE, PPRE; PPRE consensus sequence of CYP4A6 gene. The DNA-protein complexes are indicated
by arrow. (C) Effect of mutation on the protein binding. Mutant probes and NF-Y consensus sequence were used as competitors. N; NF-Y,
PR: PPAR/ RXR-α  complex. 
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data indicate, that NF-Y as well as RXR-α, a hete-
romeric partner of PPAR isoforms, may bind to the 
region (Figure 4A). The luciferase assay suggested 
the relative importance of mut1 and mut2 (Figure 5A). 
Both mut1 and mut1+2 showed reduced promoter ac-
tivity, suggesting that mut1 region is important in 
PPAR-γ  driven promoter activity. Mut2 region that 
contains NF-Y binding site may help exert promoter 
activity driven by PPAR-γ . This was further confirmed 
by addition of dominant negative form of NF-Y (NF- 
Ym) which caused decreased PPAR-γ  driven promo-
ter activity (Figure 5B). 
The bind ing of PPA R -γ  to  the G LU T2 prom oter 
w as increased in  the liver of ob/ob  m ice
If the GLUT2 expression by PPAR-γ  was activated 
in diabetic states, the physical contact between PPAR-γ  
and a putative PPRE in the GLUT2 promoter should 
be confirmed. To address this question, we performed 
chromatin immunoprecipitation assay (ChIP assay) 
using lean and ob/ob mice. As shown in Figure 6, 
PPAR-α  and PPAR-γ  bind to GLUT2-PPRE very 
weakly in the lean mice. However, the binding of 
PPAR-γ to the putative PPRE (-196/-84) on the GLUT2 
promoter was increased in ob/ob mice, whereas the 
binding of PPAR-α  was not increased, indicating that 
PPAR-γ may play a role as an activator of the GLUT2 
gene expression in liver.
D iscussion
PPAR-γ  is more abundant in adipose tissue than in 
liver, or muscle (Tontonoz et al., 1994; Braissant et 
al., 1996). However, improvement in glucose homeo-
stasis by PPAR-γ  ligand treatment involves insulin 
sensitization in muscle and liver (Inzucchi et al., 
1998). Molecular mechanism of actions of TZDs in the 
glucose homeostasis occurring in tissues other than 
adipose tissues remains elusive. Direct effects of 
TZDs on glucose uptake in L6 myotubes have been 
identified (Ciaraldi et al., 1990; Zhang et al., 1994), 
which is supported by increased activity of the 
glucose transporter GLUT4 and of PI-3-kinase (Yone-
Figure  5 . Effect of mutation on the GLUT2 promoter activity in the Alexander cells. (A) mut1, mut2, and mut1+2 were generated from pMGT2d-389
(wt) using site-directed mutagenesis. The reporter constructs containing a wild and mutant sequence of mouse GLUT2 promoter were transfected
with or without expression vectors of PPAR-γ  and RXR-α . 2 µ M rosiglitazone and 1 µ M 9-CR  ligands for receptors were treated after transfection.
(B) Role of NF-Y on the PPAR-γ  driven GLUT2 promoter activity. The wild type pMGT2-1112 reporter construct was transfected into Alexander
cells with or without expression vectors of PPAR-γ /RXR-α  and NF-Ym as indicated. All results were normalized with respect to β -galactosidase
activities. The results were shown as relative fold increase of luciferase activities compared to those of control. Results are the mean ± S.D.
of three independent experiments in triplicate.
F ig u re  6 . Chromatin immunoprecipitation (ChIP) assay. Equivalent 
amounts of DNA extracted from chromatin from lean and ob/ob m ice,
and chromatin were precipitated using 1 µ g of PPAR-α  or PPAR-γ
antibody. The GLUT2-PPRE (-196/-184 bp) region was amplified by 
PCR. In order to normalize the amount of chromosomal DNA used
in immunoprecipitation between groups, input chromatin (one hund-
redth of chromosomal DNA used for immunoprecipitation) was also
used. Detailed PCR conditions and methods of sample treatment were
described in the `Materials and Methods'. M , Marker.
PPRE
-196 -184
M Input No Ab PPAR-α PPAR γ-
Antibodies
Lean
ob/ob
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mitsu et al., 2001). On the other hand, PPAR-γ  sti-
mulated the promoter activity of genes responsible for 
glucose sensing apparatus of pancreatic β -cells, sug-
gesting that this ligand could also improve glucose- 
stimulated insulin secretion (Kim et al., 2000; 2002b). 
  In the hyperglycemic states of type 2 diabetes, 
administration of TZDs causes amelioration of blood 
glucose level, suggesting that the liver glucose sensor 
can be a direct target of TZDs action. Previously, we 
have shown that LGK is transcriptionally activated by 
TZDs in liver (Kim et al., 2004). In parallel with this 
observation, we have explored a possibility that one 
of the partner protein, GLUT2, of hepatic glucose 
sensor could be a transcriptional target of TZDs 
action in liver. 
  In this study, we have identified and localized the 
PPRE (-197 and -184 bp) in the region of mouse 
GLUT2 promoter. The mouse region is similar to 
authentic DR+1 sequence (Palmer et al., 1995), and 
activated by TZDs treatment. Currently, the contri-
bution of PPAR-γ  in hepatic gene regulation in phy-
siological state is challenged by the limited expression 
of PPAR-γ  compared to that of PPAR-α  (Way et al., 
2001). However, in pathological state of type 2 diabe-
tes or severe obesity, the liver was shown to overex-
press PPAR-γ isoforms (Rahimian et al., 2001). Thus, 
the GLUT2 expression in liver could be activated by 
TZDs in the type 2 diabetes patients. Even in the 
pathological conditions, PPAR-α  is more abundant 
than PPAR-γ. The DR+1 sequence in the GLUT2 may 
bind either PPAR-α /RXR-α  or PPAR-γ /RXR-α . Then, 
why PPAR-α /RXR-α  cannot activate the GLUT2 pro-
moter? And, how the PPAR-γ/RXR-α  can activate the 
GLUT2 promoter? To address these questions, we 
have performed the ChIP assay using mouse GLUT2 
promoter. As shown, the binding of PPAR-γ to GLUT2 
promoter is increased in the ob/ob mice, where 
PPAR-γ  is overexpressed. From this experiment, it is 
concluded that the binding of PPAR-γ  to GLUT2 
promoter is increased in the diabetic or obese mice, 
where PPAR-γ  is known to be overexpressed. 
  EMSA study suggested that mut1 and mut2 might 
constitute DR+1 site. However, competition and su-
pershift experiment showed that the slow migrating 
band (upper band, Figure 4C) contains NF-Y. NF-Y 
binds CCAAT boxes located within 100 bp upstream 
from the transcription start sites, and these elements 
are known to be important for early functions in the 
formation of preinitiation complex (Dorn et al., 1987; 
Milos et al., 1992). NF-Y also has been reported to 
interact with transcription factors binding to upstream 
promoter cis-elements of gene. Among several CCAAT- 
binding proteins including Y-box factors, CTF/NF-1, 
NF-Y and C/EBP, NF-Y is the most ubiquitous and 
specific key proximal promoter factor in the trans-
criptional regulation of different eukaryotic genes. Un-
like other CCAAT-binding proteins, NF-Y has an 
absolute requirement of CCAAT pentanucleotide as 
well as a strong preference for specific flanking se-
quences (Matuoka et al., 1999). The mechanism of 
regulating the expression of these genes cannot be 
simply due to NF-Y DNA binding. It is likely that ad-
ditional factors might be involved in the action of 
NF-Y. Indeed, previous studies from other groups 
have suggested that NF-Y interacts, either functionally 
or physically, with other transcription factors or n-
uclear proteins both in vitro and in vivo (Framson et 
al., 1993; Zwicker et al., 1995; Ericsson et al., 1996). 
In this system, the contribution of NF-Y transacting 
factor to PPAR-γ action was confirmed by the addition 
of dominant negative form of NF-Y (NF-Ym), which 
reduced the promoter activity by 65%. The contribu-
tion of NF-Y to other transcription factors has been 
reported (Lee et al., 2003). However, a molecular 
mechanism or interaction between NF-Y and transa-
cting factors needs to be explored. 
  In conclusion, we have identified a functional PPRE 
in the GLUT2 promoter in liver, and showed that 
PPAR-γ could bind to this element, and increased the 
transcription of GLUT2 mRNA in the ob/ob mice 
where appropriate amount of PPAR-γ  is expressed. 
Thus, it is assumed that PPAR-γ  may have a direct 
activating role for the hepatic GLUT2 and LGK (Kim 
et al., 2004), which help the transport of glucose into 
hepatocytes.
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